NCT01411800View on ClinicalTrials.gov

An Open-Label Study of Two Formulations of LX1033 in Healthy Human Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

August 31, 2011

Primary Completion Date

October 31, 2011

Study Completion Date

May 31, 2012

Conditions
Irritable Bowel Syndrome
Interventions
DRUG

250 mg capsule

Two 250 mg capsules will be administered for 500 mg dose

DRUG

250 mg tablets

Two 250 mg tablets will be administered for a 500 mg dose

Trial Locations (1)

66211

Lexicon Investigational Site, Overland Park

Sponsors
All Listed Sponsors
lead

Lexicon Pharmaceuticals

INDUSTRY